LavaAmp Venture Forum Presentation
-
Upload
fredcobio -
Category
Technology
-
view
776 -
download
1
description
Transcript of LavaAmp Venture Forum Presentation
Business Summary portable, rapid, and inexpensive
Better, faster cheaper technology platform
The Market: 4.4 million Tests/day
The Market Market Definition
Food Safety testing Geographic: US (technology driven) Implications for remote-low resource
applications Market Opportunity: Food
Testing $2.5B USD: 48.5% of micro market in‘08 Growth Trends: ~9%/yr in revenue, shift
from “classical” microbiology to “rapid” testing platforms
ProjectionsCOSTS Revenue Profit
2010 $ 376 $ - $ (376)
2011 $ 1,823 $ 1,350 $ (473)
2012 $ 3,693 $ 3,270 $ (423)
2013 $ 4,616 $ 8,700 $ 4,084
2014 $ 5,540 $ 15,225 $ 9,685
Competitive Environment Direct Competitors: Mini PCR devices
Idaho Technology, Inc. The Ruggedized Advanced Pathogen Identification Device (R.A.P.I.D.) system
JBAIDS (Joint Biological Agent Identification and Diagnostic System) Funding $3.3 MM 11/09 $3.6MM 7/09
High power consumption (110V), 50 lbs, 3-color fluorescence (=$$$), cost
Indirect Competitors (other ways in which customers could solve their needs) Celsis Rapid Detection Systems Classic microbiology CROs
bioMerieux Fisher Scientific
Classic PCR, Real-time PCR
The Company We are a diverse team, spread between the
US and Latin America, with both the vision and audacity to try to change the way molecular biology is done and make it affordable to millions, creating new markets and applications.
Management & Personnel Overview of Management Team
Joseph Jackson Guido Nunez-Mujica Jim Hardy Biodesic (Rik Wehbring, Rob Carlson)
Staffing Future Needs: Sales and Marketing All part timers while we work on funding Full time commitment, Sales, Operations
and logistics
Strategic Partnerships Overview of Strategic Partnerships
(if applicable) Biodesic: Engineering services
Access to funding WIRED
Publicity Technology
SciFoo Google factor
Funding Scenario $2 MM in Equity Follow-on for addition licensing and
R&D Uses of Funds
Research leading to clinical certification Licensing Injection molds, Capital improvements
for scale up operations Repayment/Exit Options
Sustainable Business M&A